Intravenous Indomethacin Therapy in Premature Infants With Patent Ductus Arteriosus: Causes of Death and One-Year Follow-up

Tsu F. Yeh, Amin Thalji, Rosita S. Pildes

研究成果: 雜誌貢獻文章

10 引文 斯高帕斯(Scopus)

摘要

Fifty-five infants participated in a double-blind study of indomethacin therapy for the closure of patent ductus arteriosus. Seventeen infants died. There was no significant difference in autopsy findings between the groups with respect to pneumonia, disseminated intravascular coagulopathy, necrotizing enterocolitis, sepsis, intraventricular hemorrhage, hydrocephalus, kernicterus, brain softening, and renal damage. For those infants who survived and returned for follow-up at approximately 1 year of age, there was no significant difference between the control (n = 17) and indomethacin (n = 13) groups with respect to physical growth, Bayley scores, respiratory infection, abnormal eye ground, neurological defects, and abnormal EEG. Four in the control group (24%) and three in the indomethacin group (23%) had moderate to severe neurological defects and/or scored less than 80 on the Bayley Mental Development Index or Psychomotor Development Index. It appeared that indomethacin therapy did not have a long-term adverse effect on premature infants.

原文英語
頁(從 - 到)803-807
頁數5
期刊American Journal of Diseases of Children
136
發行號9
DOIs
出版狀態已發佈 - 一月 1 1982
對外發佈Yes

    指紋

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health

引用此